Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
ascopubs.org

Use of PTEN protein dosage to predict for underlying germ-line PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

The APC I1307K polymorphism as a significant risk factor for CRC in average-risk Ashkenazi Jews. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not include a ...
News Medical

Serum modified PTEN levels associated with increased risk of kidney function decline

High levels of a polyubiquinated form of phosphatase and tensin homolog (PTEN) were associated with an almost four-fold higher risk of a 40% decline in kidney function in a cohort of American Indians ...
ascopubs.org

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P

Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or ...